J Neurocrit Care.  2021 Dec;14(2):88-97. 10.18700/jnc.210019.

Neuroleptic malignant syndrome cases in a Moroccan intensive care unit: a retrospective analysis and literature review

• Touzani S
• Hamdouni M
• Houari N
• Khbiza YY
• Elbouazzaoui A
• Boukatta B
• Kanjaa N

• KMID: 2523718
• DOI: http://doi.org/10.18700/jnc.210019

Abstract

Background
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening neuropsychiatric emergency. The aim of our study was to update our bedside procedures by investigating NMS cases managed in the intensive care unit (ICU).
Methods
This retrospective study included all NMS patients admitted to our hospital between January 2012 and December 2019. The variables analyzed included demographics, diagnosis, therapeutics, and outcomes.
Results
This study included 20 patients, with an average age of 36.6 years. The male to female ratio was 1:4. No patient had a history of NMS, and 60% of the patients had schizophrenia. First-generation neuroleptics (NLs) were the most commonly prescribed drugs (80%). The mean time between the introduction of NLs and onset of symptoms was 7.6 days. Rigidity was observed in 90% of the patients, hyperthermia and neuropsychic syndrome in 65%, and dysautonomia in 50%. The creatine phosphokinase level in all patients was four times the normal value. Mechanical ventilation was required in 20% of the patients and hemodialysis in one patient. None of the patients received specific therapy. The mean duration of ICU stay was 10 days. The mortality rate was 10%,, mainly associated with renal failure. The analysis of the predictors of mortality was limited by the size of our cohort.
Conclusion
NMS is a rare condition requiring multidisciplinary implementation of contextualized and updated procedures. Early detection and supportive treatment could improve the prognosis in resource-limited settings, where specific treatments are not available. Predictive risk factors should be investigated in larger multicenter cohorts.

Keyword

Neuroleptic malignant syndrome; Intensive care unit; Antipsychotics; Mortality; Treatment

Reference

1. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77:185–202.

2. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50:18–25.

3. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016; 24:97–103.

4. American Psychiatric Association. DSM-5: diagnostic and statistical manual of mental disorders. 5th ed. Arlingtone, VA: American Psychiatric Publishing;2013.

5. Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007; 48:205–11.

6. Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017; 135:398–408.

7. Strugnell C, Dunstan DW, Magliano DJ, Zimmet PZ, Shaw JE, Daly RM. Influence of age and gender on fat mass, fat-free mass and skeletal muscle mass among Australian adults: the Australian diabetes, obesity and lifestyle study (AusDiab). J Nutr Health Aging. 2014; 18:540–6.

8. Bergen SE, O'Dushlaine CT, Lee PH, Fanous AH, Ruderfer DM, Ripke S, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. Schizophr Res. 2014; 154:48–53.

9. Panagiotakopoulos L, Neigh GN. Development of the HPA axis: where and when do sex differences manifest? Front Neuroendocrinol. 2014; 35:285–302.

10. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960; 118:145–52.

11. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164:870–6.

12. Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet. 2003; 117:57–60.

13. Sahin A, Cicek M, Gonenc Cekic O, Gunaydin M, Aykut DS, Tatli O, et al. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. Turk J Emerg Med. 2017; 17:141–5.

14. Menon V, Thamizh JS, Rajkumar RP, Selvakumar N. Neuroleptic malignant syndrome (or malignant extrapyramidal autonomic syndrome): time to revisit diagnostic criteria and terminology? Aust N Z J Psychiatry. 2017; 51:102.

15. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014; 130:52–60.

16. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015; 13:395–406.

17. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999; 156:169–80.

18. Wagner R, Fink RH, Stephenson DG. Effects of chlorpromazine on excitation-contraction oupling events in fast-twitch skeletal muscle fibres of the rat. Br J Pharmacol. 2004; 141:624–33.

19. Anglin RE, Rosebush PI, Mazurek MF. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ. 2010; 182:E834–8.

20. Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010; 64:79–87.

21. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142:1137–45.

22. Gupta V, Magon R, Mishra BP, Sidhu GB, Mahajan R. Risk factors in neuroleptic malignant syndrome. Indian J Psychiatry. 2003; 45:30–5.

23. Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl). 2015; 232:1–5.

24. Benazzi F. Neuroleptic malignant syndrome without rigidity. Ital J Neurol Sci. 1991; 12:121.

25. Özdemir İ, Kuru E, Safak Y, Tulacı RG. A neuroleptic malignant syndrome without rigidity. Psychiatry Investig. 2018; 15:226–9.

26. Caroff SN, Mann SC, Campbell E. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann. 2000; 30:314–21.

27. Vörös V, Osváth P, Fekete S, Tényi T. Antipsychotics and rhabdomyolysis: differential diagnosis and clinical significance of elevated serum creatine kinase levels in psychiatric practice. Psychiatr Hung. 2009; 24:175–84.

28. Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017; 37:67–71.

29. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011; 72:1222–8.

30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatry Association;1994.

31. Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017; 13:161–75.

32. Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol. 2018; 157:663–75.

33. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995; 15:365–71.

34. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005; 135:249–56.

35. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009; 361:62–72.

36. Schönfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M, Neu P, Connemann BJ, Gahr M, et al. Treatment of the neuroleptic malignant syndrome in international therapy guidelines: a comparative analysis. Pharmacopsychiatry. 2020; 53:51–9.

37. Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm. 2013; 70:34–42.

38. Hirjak D, Sartorius A, Kubera KM, Wolf RC. Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 2: catatonic symptoms and neuroleptic malignant syndrome. Nervenarzt. 2019; 90:12–24.

39. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14:2–44.

40. Kadiyala PK, Kadiyala LD. Anaesthesia for electroconvulsive therapy: an overview with an update on its role in potentiating electroconvulsive therapy. Indian J Anaesth. 2017; 61:373–80.

41. Mahendran R, Winslow M, Lim D. Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry. 2000; 34:699–700.

42. Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018; 20:17r02185.

43. Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012; 73:427–30.

44. Taniguchi N, Tanii H, Nishikawa T, Miyamae Y, Shinozaki K, Inoue Y, et al. Classification system of complications in neuroleptic malignant syndrome. Methods Find Exp Clin Pharmacol. 1997; 19:193–9.

45. Jouali T, Boukatta B, Bechri B, Houari N, Bouazzaoui A, Sbai H, et al. A neuroleptic malignant syndrome complicated by subarachnoid hemorrhage and revealing cerebral vasculitis. Pan Afr Med J. 2014; 19:247.